Hypercalcemia - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 32

Hypercalcemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H1 2012', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypercalcemia.
- A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypercalcemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypercalcemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypercalcemia pipeline depth and focus of Hypercalcemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hypercalcemia Therapeutic Products under Development, Key Players in Hypercalcemia Therapeutics, Hypercalcemia Pipeline Overview, Hypercalcemia Pipeline, Hypercalcemia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercalcemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercalcemia
Hypercalcemia Therapeutics under Development by Companies
Hypercalcemia Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hypercalcemia Therapeutics – Products under Development by Companies
Hypercalcemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hypercalcemia Therapeutics Development
Med Discovery SA
Hypercalcemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Parathyroid Hormone (1-34) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDAB16 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercalcemia Therapeutics - Dormant Products
Hypercalcemia – Product Development Milestones
Featured News & Press Releases
Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis
Jun 04, 2007: Phase 2 Clinical Results of Ganite® Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite® and Genasense®
Mar 02, 2006: Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
Dec 05, 2004: Ganite® Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting
Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research
Sep 18, 2003: FDA Approves Genta's First Product, Ganite, for the Treatment of Cancer - Related Hypercalcemia
Apr 10, 2003: New Study Shows Biomarkers May Determine Responsiveness to Ganite in Non-Hodgkin's Lymphoma
Apr 01, 2003: Genta Completes FDA Submission of New Drug Application for Ganite; (gallium nitrate injection)
Jan 03, 2003: Genta Announces Reactivation of New Drug Application (NDA) for Ganite and Initiation of CMC Regulatory Filings Submissions Intended to Enable Product Launch during 2003
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypercalcemia, H1 2012
Products under Development for Hypercalcemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Med Discovery SA, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hypercalcemia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hypercalcemia, H1 2012
Products under Development for Hypercalcemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013